← All trials
NCT05108259
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2022
- Primary completion
- Aug 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Nov 4, 2021
- Last posted
- Nov 4, 2021
- Enrollment
- 324
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Prestige BrandsLead sponsor
- Prestige BrandsStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.